ATLASATLAS fair value
€0.783
Above fair value · 95% premium
Range: €0.705–€0.861Fair valuePrice
Lavipharm (LAVI.AT)
Lavipharm stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · Athens Stock Exchange · Greece
€1.53▲ +0.53%
Prices as of Oct 27, 2026 · EUR
Chance of rising in 1 month
52%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Lavipharm in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Lavipharm
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS estimates Lavipharm's fair value at about €0.783 per share (reasonable range: €0.705 to €0.861). At €1.53, the stock trades 95% above it.
It is calculated with valuation multiples of comparable companies. Confidence in the estimate is medium. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Lavipharm a 52% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between €1.47 and €1.60; in 9 out of 10, between €1.36 and €1.72. Estimated annual volatility is 21%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- €259M
- Market cap (USD)
- $289M
- P/E ratio
- 49.9
- Dividend yield
- 1.33%
- 52-week high
- €1.74
- 52-week low
- €0.781
- Revenue (12 months)
- €70.3M
- Gross margin
- 47.1%
- Operating margin
- 13.6%
- Net margin
- 8.2%
- Beta
- 1.01
What this means
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Lavipharm sits above fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks LAVI.AT has traded between €0.781 and €1.74. Today it is 12.2% below that high and 95% above its low.
On the business: net margin is 8.2%; it trades at 49.9 times earnings.
Its beta is 1.01: it moves roughly in line with the market.
About the company
Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sale, and wholesaling of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally.
Want to see everything about Lavipharm?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What is Lavipharm (LAVI.AT) fair value?
About €0.783 per share according to ATLAS (reasonable range: €0.705 to €0.861). With the stock at €1.53, it is 95% above it.
What is the chance LAVI.AT goes up next month?
52%: close to a coin flip. In half of the simulated outcomes, LAVI.AT ends the month between €1.47 and €1.60.
How big is Lavipharm and what is its P/E ratio?
Lavipharm's market capitalization is €259M. Its price-to-earnings (P/E) ratio is 49.9: you pay €49.9 for each €1.00 of yearly earnings.
Does Lavipharm pay a dividend?
Yes. LAVI.AT's current dividend yield is 1.33% at today's price (€1.53).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer